Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 17
Maximum Age: 45
Healthy Volunteers: f
View:

• Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy;

• No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound

• Have a desire for remaining reproductive function or uterus

• Good compliance with adjunctive treatment and follow-up

Locations
Other Locations
China
Wang Jianliu
RECRUITING
Beijing
Contact Information
Primary
WANG JIANLIU, PhD/MD
wangjianliu1203@163.com
+861088324383
Backup
HE YIJIAO, PhD
heyijiao2017@pku.edu.cn
+8618301512017
Time Frame
Start Date: 2023-01-06
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 82
Treatments
Experimental: Experimental group
MPA + Atorvastatin
No_intervention: Control groups
MPA
Related Therapeutic Areas
Sponsors
Leads: Peking University People's Hospital

This content was sourced from clinicaltrials.gov